Presentation is loading. Please wait.

Presentation is loading. Please wait.

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Published byΝικόλαος Γαλάνη Modified over 5 years ago

Similar presentations

Presentation on theme: "Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry."— Presentation transcript:

1 Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction; MI, myocardial infarction; NSTEMI, non... Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction; MI, myocardial infarction; NSTEMI, non-ST segment elevation myocardial infarction; STEMI, ST segment elevation myocardial infarction. Francois Schiele et al. Open Heart 2016;3:e000384 ©2016 by British Cardiovascular Society

Download ppt "Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry."

Similar presentations

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.
Discontinuation of medication after nonfatal event: MI

Discontinuation of medication after nonfatal event: MI
Risk stratification in ACS F.Shakib .cardiologigst

Risk stratification in ACS F.Shakib .cardiologigst
Figure 1 Patient flow chart.

Figure 1 Patient flow chart.
Ischemic Heart Disease

Ischemic Heart Disease
Copyright © 2009 American Medical Association. All rights reserved.

Copyright © 2009 American Medical Association. All rights reserved.
Discharge Heart Rate and Mortality after Acute Myocardial Infarction

Discharge Heart Rate and Mortality after Acute Myocardial Infarction
Manuel Caceres, MD, Darryl S. Weiman, MD, JD 

Manuel Caceres, MD, Darryl S. Weiman, MD, JD 
Baseline characteristics of patients

Baseline characteristics of patients
Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
Section A: Introduction

Section A: Introduction
Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)

Death, target vessel revascularisation (TVR) and myocardial infarction (MI) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES)
Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.
Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials
Figure 1 PCI strategies in patients with STEMI and multivessel disease

Figure 1 PCI strategies in patients with STEMI and multivessel disease
P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.
Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding  Surasak Saokaew, PharmD, Narinee Khaisombat, MSc, Nathorn Chaiyakunapruk,

Attributable Cost and Length of Stay for Patients with Enoxaparin-Associated Bleeding  Surasak Saokaew, PharmD, Narinee Khaisombat, MSc, Nathorn Chaiyakunapruk,
Figure 4 Observational studies on multiple treatment strategies

Figure 4 Observational studies on multiple treatment strategies
Prakash Harikrishnan et al. JACEP 2015;1:

Prakash Harikrishnan et al. JACEP 2015;1:
The recommended approach to patients with chronic obstructive pulmonary disease (COPD) presenting with dyspnoea. The recommended approach to patients with.

The recommended approach to patients with chronic obstructive pulmonary disease (COPD) presenting with dyspnoea. The recommended approach to patients with.

Similar presentations

Ads by Google